Across TCGA pan-cancer cohorts, TRAV26-2 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated TRAV26-2 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher TRAV26-2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TRAV26-2 expression acts as an unfavorable survival marker.

LUAD and SKCM are the cancer types where TRAV26-2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.171	0.835	<.001	24	view →
SKCM	DFS	Median	All	0.226	0.757	.037	3	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: TRAV26-2 tumor-vs-normal RNA expression · all TRAV26-2 data types